Cancers, chronic diseases and respiratory infections are major causes of mortality and present diagnostic and therapeutic challenges for health care. There is an unmet medical need for non-invasive, easy-to-use biomarkers for the early diagnosis, phenotyping, predicting and monitoring of the therapeutic responses of these disorders. Exhaled breath sampling is an attractive choice that has gained attention in recent years. Exhaled nitric oxide measurement used as a predictive biomarker of the response to anti-eosinophil therapy in severe asthma has paved the way for other exhaled breath biomarkers. Advances in laser and nanosensor technologies and spectrometry together with widespread use of algorithms and artificial intelligence have facilitated research on volatile organic compounds and artificial olfaction systems to develop new exhaled biomarkers. We aim to provide an overview of the recent advances in and challenges of exhaled biomarker measurements with an emphasis on the applicability of their measurement as a non-invasive, point-of-care diagnostic and monitoring tool.
Background: Post-COVID-19 syndrome, characterized by persistent symptoms emerging more than 12 weeks after acute infection, displays diverse manifestations. This study aimed to analyze co-existing organ dysfunctions in post-COVID-19 patients and explore their potential association with the acute COVID-19 episode and functional impairment. Methods: Data from 238 patients attending post-COVID-19 outpatient care between 1 March 2021 and 1 March 2022, after previous hospitalization for acute COVID-19, were retrospectively analyzed with 80 having comprehensive mapping of organ involvement. Results: The average time between acute episode and post-COVID-19 care was 149 days. Spirometry indicated significant abnormalities in lung function. Predominant symptoms included respiratory (75%), fatigue (73%), neurological (62.5%), and ear-nose-throat issues (51.25%). Multiorgan dysfunctions were observed in 87.5% of patients, contributing to an 18.33% reduction in health quality compared to pre-acute COVID-19 levels. Subgroup analysis identified four distinct post-COVID-19 syndrome subgroups, highlighting the coexistence of respiratory and neurological disorders as potential indicators and drivers of further organ involvement. Our results reveal that most patients with post-COVID-19 syndrome suffer from multiorgan disorders. Conclusions: The presence of coexisting respiratory and neurological symptoms suggests the involvement of other organ systems as well. The complexity of multiorgan involvement requires further studies to provide insights into the different symptom clusters and identify potential targets for personalized preventive and therapeutic interventions to improve patient outcome.
Background/Objectives: Connective tissue disease-associated interstitial lung disease (CTD-ILD) is linked to substantial morbidity and mortality. While nintedanib (NTB) slows lung function decline in progressive pulmonary fibrosis (PPF), real-world data—particularly regarding radiographic outcomes—remain limited. We aimed to evaluate the real-world effectiveness and tolerability of antifibrotic therapy—predominantly NTB—on radiographic and functional outcomes in a Hungarian CTD-ILD cohort. Methods: We conducted a retrospective observational cohort study including 72 patients with progressive CTD-ILD who initiated antifibrotic therapy at two Hungarian tertiary centers between January 2021 and June 2025. The primary endpoint was the proportion of patients without significant radiographic progression at 6–12 months, based on blinded assessment of paired high-resolution computed tomography (HRCT) scans by two thoracic radiologists. Secondary endpoints included changes in forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) at 6 and 12 months, safety and tolerability, and correlations between lung function and disease-related factors. Results: The cohort comprised systemic sclerosis–ILD (n = 25), rheumatoid arthritis–ILD (n = 23), and other CTD-ILD (n = 24). Radiographic stability was observed in 65.8–78.9% of patients, with improvement most commonly seen in ground-glass opacities, while traction bronchiectasis remained largely unchanged. Radiographic disease extent showed the strongest inverse correlation with baseline FVC and DLCO (p < 0.05). Significant improvements in FVC and DLCO were observed at 6 and 12 months (p < 0.001). Antifibrotic therapy was well tolerated, including in combination with immunosuppressive treatment. Conclusions: These real-world data support the effectiveness and safety of NTB in PPF–CTD-ILD and highlight radiologic disease burden as a key determinant of functional impairment.
Background: Although an increasing number of studies have reported 2- and 3-year outcomes of post-acute sequelae of SARS-CoV-2 infection (PASC), the long-term symptom patterns of and their clinical phenotypes beyond four years remains unknown. We aimed to characterize 48-month clinical outcomes and symptom profiles using hierarchical cluster analysis. Methods: We conducted a longitudinal cohort study of 79 patients with persistent PASC enrolled between March 2021 and March 2022. Of these, 77 patients completed the 48-month follow-up. Symptoms were assessed at 11 and 48 months post-infection. Hierarchical cluster analysis using Jaccard distance and Ward’s linkage identified symptom-based phenotypes at 48 months. Cluster membership was subsequently mapped back to 11-month symptom profiles to evaluate longitudinal trajectories. Results: Of the 77 patients completing the 48-month follow-up, symptom profiles at 48 months could be descriptively characterized into four exploratory, symptom-based profiles, which differed from the broader symptom patterns observed at month 11: Cluster 1 (cardiorespiratory and neurosensory symptoms; 16.9%, n = 13), characterized by persistent chest discomfort and palpitations; Cluster 2 (musculoskeletal/pain-predominant; 33.8%, n = 26), characterized by persistent myalgia and arthralgia. Cluster 3 (neurocognitive and mixed multisystem profile; 23.4%, n = 18), characterized by persistent cognitive impairment and musculoskeletal pain and Cluster 4 (minimal residual symptom burden; 26.0%, n = 20), demonstrating the lowest overall residual symptom burden at 48 months. Conclusions: At 48 months, PASC symptoms showed substantial heterogeneity, with four exploratory symptom-based profiles. In our cohort, over one-quarter of patients had the lowest observed residual symptom burden at 48 months; neurocognitive and musculoskeletal symptoms remained prominent in specific profiles, supporting the need for targeted multidisciplinary post-acute care.
The complement system is a key link between innate and adaptive im-munity, participating in the elimination of pathogens, the regulation of immune responses and the maintenance of tissue homeostasis. Its activa-tion is not only crucial in infections, such as COVID-19, but also plays a prominent role in the pathomechanism of several non-infectious respira-tory diseases, such as asthma, COPD, sarcoidosis and lung cancer. Com-plement components can influence the quality of the adaptive response, including through the regulation of T2 immunity and eosinophilic in-flammation, thereby linking natural defense to complex immune process-es. In recent years, it has become increasingly clear that dysregulation of the complement system contributes to the development of inflammation, thrombosis and tissue damage in a wide range of respiratory diseases. The study of the various components of this cascade system may therefore be promising from both a diagnostic and therapeutic point of view. Some of its components may serve as biomarkers for distinguishing between dif-ferent phenotypes of certain lung diseases, while their targeted inhibition or modulation may open the way towards new treatment options. A better understanding of the complement system's connecting role not only allows for a deeper exploration of immunological relationships, but may also bring us closer to personalised, immunology-based pulmonology, which may have real clinical benefits in the future.
The complement system is a key link between innate and adaptive immunity, contributing to pathogen elimination, immune regulation, and tissue homeostasis. Its activation is not only crucial in infections, such as COVID-19, but also plays a major role in the pathomechanism of several non-infectious respiratory diseases, such as asthma, COPD, sarcoidosis and lung cancer. Complement components can modulate the quality of the adaptive immune responses, including through the regulation of T2 immunity and eosinophilic inflammation, thereby linking natural defense to complex immune processes. In recent years, it has become increasingly clear that dysregulated complement activity contributes to inflammation, thrombosis and tissue damage in a wide range of respiratory diseases. The study of the various components of this cascade system may therefore be promising from both a diagnostic and therapeutic point of view. Some of its components may serve as biomarkers for distinguishing between different phenotypes of certain lung diseases, while their targeted inhibition or modulation may open the way towards new treatment options. A better understanding of the complement system’s integrative and regulatory role not only allows for a deeper insight into immunological interactions but may also bring us closer to phenotype-oriented, immunology-based pulmonology, which may have real clinical benefits in the future.